Exact Mass: 485.1175974000001

Exact Mass Matches: 485.1175974000001

Found 126 metabolites which its exact mass value is equals to given mass value 485.1175974000001, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Ketotifen-N-glucuronide is a metabolite of ketotifen. Ketotifen is a second-generation H1-antihistamine and mast cell stabilizer. It is most commonly sold in as a salt of fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks. Side effects include drowsiness, weight gain, dry mouth, irritability, and increased nosebleeds. (Wikipedia)

Fluoxetine glucuronide

(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amino]oxane-2-carboxylic acid

C23H26F3NO7 (485.16612820000006)

Fluoxetine glucuronide is a metabolite of fluoxetine. Fluoxetine (also known by the tradenames Prozac, Sarafem, Fontex, among others) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Fluoxetine was first documented in 1974 by scientists from Eli Lilly and Company. It was presented to the U.S. Food and Drug Administration in February 1977, with Eli Lilly receiving final approval to market the drug in December 1987. Fluoxetine went off-patent in August 2001 (Wikipedia).

Afatinib

N-{4-[(3-chloro-4-fluorophenyl)amino]-7-(oxolan-3-yloxy)quinazolin-6-yl}-4-(dimethylamino)but-2-enamide

C24H25ClFN5O3 (485.1629862)

Canertinib

N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide

C24H25ClFN5O3 (485.1629862)

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor

Dibutyryl cyclic gmp

[6-(2-butanamido-6-oxo-6,9-dihydro-1H-purin-9-yl)-2-hydroxy-2-oxo-tetrahydro-2H-2lambda5-furo[3,4-d][1,3,2]dioxaphosphol-4-yl]methyl butanoate

C18H24N5O9P (485.13115840000006)

o2',o3',o5'-Tri-acetyl-n6-(3-hydroxyphenyl)adenosine

[3,4-bis(acetyloxy)-5-{6-[(3-hydroxyphenyl)amino]-9H-purin-9-yl}oxolan-2-yl]methyl acetate

C22H23N5O8 (485.1546558)

ZINC8647836

C25H19N5O2S2 (485.0980114)

beta-hydroxyorcein

C28H23NO7 (485.1474448)

A member of the class of phenoxazines that is 1,9-dimethyl-3H-phenoxazin-3-one carrying an additional hydroxy substituent at position 7 as well as two 2,4-dihydroxy-6-methylphenyl substituents at positions 2 and 8. The isomer in which the hydroxy groups at positions 2 and 2 on the phenyl rings are both on the same side of the plane of the phenoxazine ring system. A component of orcein, a mixture of dyes isolated from lichens.

3-carboxy-indole-10-O-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyl ester|chaihuxinoside B

C21H27NO12 (485.15331820000006)

m-digalloyl L-tyrosine

C23H19NO11 (485.0958064)

6-methoxyaristolactam I N-beta-glucoside

C24H23NO10 (485.1321898)

9-O-Methylstecepharine

C22H28ClNO9 (485.1452508000001)

Cys Cys Phe Asn

(2S)-2-[(2S)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-phenylpropanamido]-3-carbamoylpropanoic acid

C19H27N5O6S2 (485.1402682)

Cys Cys Asn Phe

(2S)-2-[(2S)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-phenylpropanoic acid

C19H27N5O6S2 (485.1402682)

Cys Phe Cys Asn

(2S)-2-[(2R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-phenylpropanamido]-3-sulfanylpropanamido]-3-carbamoylpropanoic acid

C19H27N5O6S2 (485.1402682)

Cys Phe Asn Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-phenylpropanamido]-3-carbamoylpropanamido]-3-sulfanylpropanoic acid

C19H27N5O6S2 (485.1402682)

Cys Asn Cys Phe

(2S)-2-[(2R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-phenylpropanoic acid

C19H27N5O6S2 (485.1402682)

Cys Asn Phe Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-phenylpropanamido]-3-sulfanylpropanoic acid

C19H27N5O6S2 (485.1402682)

Cys Asn Ser Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanoic acid

C19H27N5O8S (485.1580262)

Cys Asn Tyr Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanoic acid

C19H27N5O8S (485.1580262)

Cys Ser Asn Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-(4-hydroxyphenyl)propanoic acid

C19H27N5O8S (485.1580262)

Cys Ser Tyr Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-carbamoylpropanoic acid

C19H27N5O8S (485.1580262)

Cys Tyr Asn Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-carbamoylpropanamido]-3-hydroxypropanoic acid

C19H27N5O8S (485.1580262)

Cys Tyr Ser Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-carbamoylpropanoic acid

C19H27N5O8S (485.1580262)

Phe Cys Cys Asn

(2S)-2-[(2R)-2-[(2R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-carbamoylpropanoic acid

C19H27N5O6S2 (485.1402682)

Phe Cys Asn Cys

(2R)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-sulfanylpropanoic acid

C19H27N5O6S2 (485.1402682)

Phe Asn Cys Cys

(2R)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid

C19H27N5O6S2 (485.1402682)

Asn Cys Cys Phe

(2S)-2-[(2R)-2-[(2R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-phenylpropanoic acid

C19H27N5O6S2 (485.1402682)

Asn Cys Phe Cys

(2R)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-phenylpropanamido]-3-sulfanylpropanoic acid

C19H27N5O6S2 (485.1402682)

Asn Cys Ser Tyr

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanoic acid

C19H27N5O8S (485.1580262)

Asn Cys Tyr Ser

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanoic acid

C19H27N5O8S (485.1580262)

Asn Phe Cys Cys

(2R)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-phenylpropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid

C19H27N5O6S2 (485.1402682)

Asn Ser Cys Tyr

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-(4-hydroxyphenyl)propanoic acid

C19H27N5O8S (485.1580262)

Asn Ser Tyr Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-sulfanylpropanoic acid

C19H27N5O8S (485.1580262)

Asn Tyr Cys Ser

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-sulfanylpropanamido]-3-hydroxypropanoic acid

C19H27N5O8S (485.1580262)

Asn Tyr Ser Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-sulfanylpropanoic acid

C19H27N5O8S (485.1580262)

Ser Cys Asn Tyr

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-(4-hydroxyphenyl)propanoic acid

C19H27N5O8S (485.1580262)

Ser Cys Tyr Asn

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-carbamoylpropanoic acid

C19H27N5O8S (485.1580262)

Ser Asn Cys Tyr

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-(4-hydroxyphenyl)propanoic acid

C19H27N5O8S (485.1580262)

Ser Asn Tyr Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-sulfanylpropanoic acid

C19H27N5O8S (485.1580262)

Ser Tyr Cys Asn

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-sulfanylpropanamido]-3-carbamoylpropanoic acid

C19H27N5O8S (485.1580262)

Ser Tyr Asn Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-carbamoylpropanamido]-3-sulfanylpropanoic acid

C19H27N5O8S (485.1580262)

Tyr Cys Asn Ser

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-hydroxypropanoic acid

C19H27N5O8S (485.1580262)

Tyr Cys Ser Asn

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-carbamoylpropanoic acid

C19H27N5O8S (485.1580262)

Tyr Asn Cys Ser

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-hydroxypropanoic acid

C19H27N5O8S (485.1580262)

Tyr Asn Ser Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-sulfanylpropanoic acid

C19H27N5O8S (485.1580262)

Tyr Ser Cys Asn

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-carbamoylpropanoic acid

C19H27N5O8S (485.1580262)

Tyr Ser Asn Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-sulfanylpropanoic acid

C19H27N5O8S (485.1580262)

1-deoxy-1-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]-b-D-Glucopyranuronic acid

1-Deoxy-1-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]-beta-D-glucopyranuronic acid

C23H26F3NO7 (485.16612820000006)

Ketotifen-N-glucuronide

C25H27NO7S (485.15081520000007)

L-Aspartic acid dibenzyl ester 4-toluenesulfonate

C25H27NO7S (485.15081520000007)

afatinib

C24H25ClFN5O3 (485.1629862)

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells[1]. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer[1][2][3][4].

Crizotinib (hydrochloride)

C21H23Cl3FN5O (485.095213)

Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition[1][2][3].

H-D-Asp(oBzl)-oBzl.Tos

C25H27NO7S (485.15081520000007)

2,2-[[3-methyl-4-[(6-nitrobenzothiazol-2-yl)azo]phenyl]imino]bisethyl diacetate

C22H23N5O6S (485.13689780000004)

7,7-dimethyl-3-[(3-nitrophenyl)methyl]-1-(4-phenyl-1,3-thiazol-2-yl)-6,8-dihydroquinoline-2,5-dione

C27H23N3O4S (485.14091980000006)

(1S,3S,5R,6R)-(4-nitrophenylmethyl)-1-dioxo-6-phenylacetamido-penam-3-carboxylate

C23H23N3O7S (485.12566480000004)

Gemifloxacin mesylate

C19H24FN5O7S (485.1380406)

D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic The mesylate salt of gemifloxacin. D004791 - Enzyme Inhibitors

CHIR-98014

6-N-[2-[[4-(2,4-dichlorophenyl)-5-imidazol-1-ylpyrimidin-2-yl]amino]ethyl]-3-nitropyridine-2,6-diamine

C20H17Cl2N9O2 (485.08822019999997)

Regorafenib D3

C21H12D3ClF4N4O3 (485.09570733400005)

(2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[(3R)-tetrahydro-3-furanyloxy]-6-quinazolinyl}-4-(dimethylamino)-2-butenamide

C24H25ClFN5O3 (485.1629862)

(E)-ethyl 5-(benzyloxy)-6-broMo-2-(3-ethoxy-3-oxoprop-1-en-1-yl)-1-Methyl-1H-indole-3-carboxylate

C24H24BrNO5 (485.08377540000004)

4-bromo-10-phenyl-10H-spiro[acridine-9,9-fluorene]

C31H20BrN (485.07790200000005)

Afatinib iMpurity

C24H25ClFN5O3 (485.1629862)

R-Afatinib

C24H25ClFN5O3 (485.1629862)

Afabicin

C23H24N3O7P (485.1351804)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic

Asciminib hydrochloride

C20H19Cl2F2N5O3 (485.0832948000001)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

Folate disodium

C19H17N7Na2O6 (485.1035662)

N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-Butenamide

C24H25ClFN5O3 (485.1629862)

gamma-Hydroxyorcein

C28H23NO7 (485.1474448)

A member of the class of phenoxazines that is 1,9-dimethyl-3H-phenoxazin-3-one carrying an additional hydroxy substituent at position 7 as well as two 2,4-dihydroxy-6-methylphenyl substituents at positions 2 and 8. The isomer in which the hydroxy groups at positions 2 and 2 on the phenyl rings are situated on opposite sides of the plane of the phenoxazine ring system. A component of orcein, a mixture of dyes isolated from lichens.

N-[1-(Aminomethyl)cyclopropyl]-3-(benzylsulfonyl)-N~2~-[(1S)-2,2,2-trifluoro-1-(4-hydroxyphenyl)ethyl]-L-alaninamide

C22H26F3N3O4S (485.1596032000001)

[(2R,3S,4S)-5-[8-(dimethylamino)-7-methyl-2,4-dioxobenzo[g]pteridin-10-yl]-2,3,4-trihydroxypentyl] dihydrogen phosphate

C18H24N5O9P (485.13115840000006)

3-Hydroxyflavone-3-malonylglucoside

C24H21O11- (485.10838160000003)

7-hydroxyflavone 7-O-(6-malonyl-beta-D-glucoside)

C24H21O11- (485.10838160000003)

[4-[2-(butanoylamino)-6-oxo-1H-purin-9-yl]-2-hydroxy-2-oxo-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3,2]dioxaphosphol-6-yl]methyl butanoate

C18H24N5O9P (485.13115840000006)

Malachite green isothiocyanate

C24H24ClN3O4S (485.1175974000001)

N-[5-(diethylsulfamoyl)-2-(4-morpholinyl)phenyl]-2-oxo-1-benzopyran-3-carboxamide

C24H27N3O6S (485.1620482000001)

2-[[4-amino-5-(3,4-dimethoxyphenyl)-1,2,4-triazol-3-yl]thio]-1-(1H-indol-3-yl)-2-phenylethanone

C26H23N5O3S (485.15215280000007)

(2S,4S)-4-(1-benzothiophen-3-yl)-2-[[4-(hydroxymethyl)phenyl]methoxy]-N-(phenylmethyl)-3,4-dihydro-2H-pyran-6-carboxamide

C29H27NO4S (485.1660702000001)

butanoic acid [(4aS,7S,7aS)-2-hydroxy-2-oxo-6-[6-oxo-2-(1-oxobutylamino)-3H-purin-9-yl]-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphorin-7-yl] ester

C18H24N5O9P (485.13115840000006)

3-(p-carboxyphenylazo)-N-acetyl-L-tyrosylglycylglycine

C22H23N5O8 (485.1546558)

1-[(2S,3S,6R)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2S,3R,6S)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2R,3R,6R)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

(3R,6aS,8S,10aS)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide

C22H29Cl2N3O5 (485.14841640000003)

1-[(2R,3S,6S)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2S,3S,6S)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

(3S,6aR,8S,10aR)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide

C22H29Cl2N3O5 (485.14841640000003)

(3S,6aR,8R,10aR)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide

C22H29Cl2N3O5 (485.14841640000003)

1-[(2S,3R,6R)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-(4-chlorophenyl)-3-[2-[(2S,5R,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]urea

C21H25ClFN3O5S (485.11874020000005)

1-(4-chlorophenyl)-3-[2-[(2R,5S,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]urea

C21H25ClFN3O5S (485.11874020000005)

1-(4-chlorophenyl)-3-[2-[(2S,5S,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2R,3R,6R)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2S,3S,6R)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

(3S,6aS,8R,10aS)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide

C22H29Cl2N3O5 (485.14841640000003)

(1R,9S,10S,11S)-12-(2-fluorophenyl)sulfonyl-10-(hydroxymethyl)-6-oxo-5-pyridin-4-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylic acid

C23H20FN3O6S (485.10567920000005)

1-[(2R,3S,6R)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2R,3R,6S)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-(4-chlorophenyl)-3-[2-[(2R,5S,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]urea

C21H25ClFN3O5S (485.11874020000005)

1-(4-chlorophenyl)-3-[2-[(2R,5R,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]urea

C21H25ClFN3O5S (485.11874020000005)

1-(4-chlorophenyl)-3-[2-[(2R,5R,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]urea

C21H25ClFN3O5S (485.11874020000005)

1-(4-chlorophenyl)-3-[2-[(2S,5R,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2S,3R,6S)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2R,3S,6R)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2S,3S,6S)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2S,3R,6R)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2R,3S,6S)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

1-[(2R,3R,6S)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-fluorophenyl)urea

C21H25ClFN3O5S (485.11874020000005)

(3R,6aS,8R,10aS)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide

C22H29Cl2N3O5 (485.14841640000003)

(3R,6aR,8R,10aR)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide

C22H29Cl2N3O5 (485.14841640000003)

(3S,6aS,8S,10aS)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide

C22H29Cl2N3O5 (485.14841640000003)

(3R,6aR,8S,10aR)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide

C22H29Cl2N3O5 (485.14841640000003)

(1S,9R,10R,11R)-12-(2-fluorophenyl)sulfonyl-10-(hydroxymethyl)-6-oxo-5-pyridin-4-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylic acid

C23H20FN3O6S (485.10567920000005)

sodium 2-acetamido-2-deoxy-3-O-(6-O-sulfonato-beta-D-glucosyl)-beta-D-galactose

C14H24NNaO14S (485.0815164)

1-(2-methoxyphenyl)-3-[(E)-(1-methyl-5-piperidin-1-ylsulfonylindol-3-yl)methylideneamino]thiourea

C23H27N5O3S2 (485.1555232)

2-amino-4-({2-[(1-carboxy-2-hydroxy-1-methyl-2-phenylethyl)sulfanyl]-1-[(carboxymethyl)-C-hydroxycarbonimidoyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid

C20H27N3O9S (485.14679320000005)

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(2-hydroxy-4-methoxyphenyl)-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid

C20H27N3O9S (485.14679320000005)

4,7-DI(4-Methoxyphenyl)-6-(3,4-dimethoxyphenyl)-1,2.5-thiadiazolo(3,4-C)pyridine

C27H23N3O4S (485.14091980000006)

Canertinib

Canertinib (CI-1033)

C24H25ClFN5O3 (485.1629862)

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor

Fluoxetine glucuronide

1-Deoxy-1-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]-beta-D-glucopyranuronic acid

C23H26F3NO7 (485.16612820000006)

LPS 12:2;O3

C18H32NO12P (485.16620420000004)

ST 19:5;O7;Tau

C21H27NO10S (485.1355602000001)

IMM-H007

C22H23N5O8 (485.1546558)

IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis[1][2][3]. IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis[1][2][3].